Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 5/20 | 0.44 |
| ▸ | FPR2 | P25090 | 3/20 | 0.44 |
| ▸ | PRCP | P42785 | 4/20 | 0.43 |
| ▸ | MC4R | P32245 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21036774 | 1.00 | FPR1 (0.44) | FPR1FPR2PRCPMC4RHTR2C | |
| Hydrochloric Acid SCHEMBL20994326 | 0.99 | FPR1 (0.43) | FPR1FPR2PRCPMC4RHTR2C | |
| SCHEMBL29327388 | 0.87 | MC4R (0.54) | FPR1FPR2PRCPMC4RHTR2C | |
| SCHEMBL1920424 | 0.87 | MC4R (0.54) | FPR1FPR2PRCPMC4RHTR2C | |
| SCHEMBL1921102 | 0.87 | MC4R (0.54) | FPR1FPR2PRCPMC4RHTR2C | |
| SCHEMBL12533727 | 0.87 | MC4R (0.54) | FPR1FPR2PRCPMC4RHTR2C | |
| SCHEMBL8223289 | 0.85 | PRCP (0.45) | FPR1FPR2PRCPMC4RHTR2C | |
| SCHEMBL684171 | 0.85 | PRCP (0.45) | FPR1FPR2PRCPMC4RHTR2C | |
| SCHEMBL1920197 | 0.85 | FPR1 (0.48) | FPR1FPR2MC4RKCNH2 | |
| SCHEMBL29904547 | 0.84 | PRCP (0.46) | FPR1FPR2PRCPMC4RHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710988-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | FPR1 469/4885FPR2 340/4885PRCP 1156/4885 |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | GPR4, MC4R, TRPC4 | FPR1 469/4885FPR2 340/4885PRCP 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.